Brenig Therapeutics has raised $65 million to advance its lead candidate, LRRK inhibitor BT-267, into human clinical trials as a possible treatment for idiopathic (of unknown cause) and LRRK2-associated Parkinson’s disease. The funds will be used to test BT-267 in healthy volunteers in a first-in-human study, Brenig said.
The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded a $6 million grant to Lario Therapeutics to advance early studies into CaV2.3 calcium channel inhibitors as a potential disease-modifying therapy for Parkinson’s disease. Lario’s preclinical program is being developed in collaboration with the Oxford…
Scientists have discovered a link between a mutation in the CARS gene and late-onset neurological disorders with symptoms, such as movement disorder, similar to those seen in Parkinson’s disease patients. The mutation, known as CARS E795V, was identified as the cause of a neurological condition affecting nine people…
A model that uses artificial intelligence (AI) to analyze electroencephalography (EEG)-based patterns of brain activity showed a potential to accurately diagnose Parkinson’s disease at early stages, according to a recent study from Australia. EEG, a non-invasive way of studying the brain’s electrical activity, is used to detect patterns of…
Four endurance athletes, one of whom has Parkinson’s disease, have embarked on a 2,800-mile rowing journey across the Pacific Ocean this summer. The team’s goal is to raise $28 million for Parkinson’s research through The Michael J. Fox Foundation for Parkinson’s Research(MJFF). The “Team Human Powered Potential” aims…
Low levels in the cerebrospinal fluid (CSF) — the liquid surrounding the brain and spinal cord — of proteins associated with nerve cell function may help in the early diagnosis of people with progressive supranuclear palsy (PSP), a form of atypical parkinsonism, according…
AskBio’s investigational gene therapy AB-1005 has been granted fast-track designation for Parkinson’s disease by the U.S. Food and Drug Administration (FDA), and innovation passport designation by the regulatory agency in the U.K. These designations are meant to accelerate the development and review process of therapy candidates designed to…
Anew Medical said it will advance clinical development of its Klotho gene therapy program to prevent or stop the progression of neurodegenerative diseases, including Parkinson’s disease. Initial data suggest that maintaining high levels of the Klotho protein in the body may help people live longer and healthier…
Kannalife Sciences has been awarded a $1.49 million grant from The Michael J. Fox Foundation (MJFF) to support the development of KLS-13019, the company’s novel cannabidiol- or CBD-derived therapy targeting neuroinflammation and mitochondrial dysfunction in Parkinson’s disease. KLS-13019 has shown promising results in preclinical models of…
The Aligning Science Across Parkinson’s (ASAP) initiative has launched a data-sharing platform that will make data on human brain samples available to researchers around the world, furthering research into Parkinson’s disease. The ASAP CRN Cloud includes several brain sequencing collections obtained from samples from four ASAP Collaborative…
Get regular updates to your inbox.